216 related articles for article (PubMed ID: 25886409)
1. Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
Park JH; Ryu MH; Park YS; Park SR; Na YS; Rhoo BY; Kang YK
BMC Cancer; 2015 Mar; 15():119. PubMed ID: 25886409
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
3. mTOR as a therapeutic target in patients with gastric cancer.
Al-Batran SE; Ducreux M; Ohtsu A
Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
[TBL] [Abstract][Full Text] [Related]
4. Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an
Parachoniak CA; Rankin A; Gaffney B; Hartmaier R; Spritz D; Erlich RL; Miller VA; Morosini D; Stephens P; Ross JS; Keech J; Chmielecki J
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28550065
[TBL] [Abstract][Full Text] [Related]
5. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
Kim ST; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
BMC Cancer; 2017 Mar; 17(1):211. PubMed ID: 28330462
[TBL] [Abstract][Full Text] [Related]
6. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
[TBL] [Abstract][Full Text] [Related]
7. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer.
Bu Z; Ji J
Curr Cancer Drug Targets; 2013 Feb; 13(2):121-5. PubMed ID: 23215721
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
10. The prognosis of patients treated with everolimus for advanced ER-positive, HER2-negative breast cancer is driven by molecular features.
Salaün H; Djerroudi L; Haik L; Schnitzler A; Bataillon G; Deniziaut G; Bièche I; Vincent-Salomon A; Debled M; Cottu P
J Pathol Clin Res; 2024 May; 10(3):e12372. PubMed ID: 38563252
[TBL] [Abstract][Full Text] [Related]
11. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
[TBL] [Abstract][Full Text] [Related]
12. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Blesius A; Beuselinck B; Chevreau C; Ravaud A; Rolland F; Oudard S; Escudier B
Clin Genitourin Cancer; 2013 Jun; 11(2):128-33. PubMed ID: 23332872
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
[TBL] [Abstract][Full Text] [Related]
15. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
[TBL] [Abstract][Full Text] [Related]
17. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Yasugi M; Takigawa N; Ochi N; Ohashi K; Harada D; Ninomiya T; Murakami T; Honda Y; Ichihara E; Tanimoto M; Kiura K
Exp Cell Res; 2014 Aug; 326(2):201-9. PubMed ID: 24768699
[TBL] [Abstract][Full Text] [Related]
18. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
20. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]